Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies.
Kleppe and colleagues use detailed cytokine profiling analyses to investigate the role of aberrant proinflammatory cytokine secretion in the pathogenesis of myeloproliferative neoplasms. Their analyses implicate constitutive activation of STAT3 in both malignant and nonmalignant bone marrow cell populations as a driver of aberrant cytokine secretion and as a cellular target mediating the therapeutic activity of ruxolitinib.
Institute for Cancer Genetics, Columbia University, New York, New York.
Laura
L
Belver
Institute for Cancer Genetics, Columbia University, New York, New York. Department of Pathology, Columbia University Medical Center, New York, New York. Department of Pediatrics, Columbia University Medical Center, New York, New York. af2196@columbia.edu.
Adolfo A
AA
Ferrando
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D006801:Humans; D053612:Janus Kinases / Q000378:metabolism*; D009196:Myeloproliferative Disorders / Q000378:metabolism*; D050791:STAT Transcription Factors / Q000378:metabolism*; D015398:Signal Transduction
D050791:STAT Transcription Factors; D053612:Janus Kinases